

1 **Article Summary Line:** A recent, nationwide mass screening program in Peru’s prisons using
2 digital radiography with automated interpretation and molecular testing identified high
3 tuberculosis prevalence and rates of rifampicin resistance, highlighting the need for active case-
4 finding as an efficient strategy to identify undiagnosed TB burden in high-risk populations.

5 **Running Title:** National Active Case-Finding for TB in Prisons

6 **Keywords:** Mycobacterium tuberculosis, tuberculosis, drug resistance, mass screening,
7 rifampicin, asymptomatic infections

8
9 **Title:** A National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024

10 **Authors:** Esther Jung*, Valentina A. Alarcón, Wilfredo Santos Solís Tupes, Tatiana Avalos-
11 Cruz, Marco Tovar, Erika Abregu, Max Z. Yang, Jason R. Andrews¹, Moises A. Huaman¹

12 ¹These senior authors contributed equally to this article.

13 *Corresponding Author: Esther Jung, Stanford University School of Medicine, 240 Pasteur Dr,
14 Stanford, CA 94304-1049, Phone: (858)260-8377, Email: esthjung@stanford.edu

15 **Affiliations:**

16 Stanford University School of Medicine, Stanford, California, USA (E. Jung, M.Z. Yang, J.R.
17 Andrews)

18 Dirección de Prevención y Control de Tuberculosis (DPCTB), Ministerio de Salud, Lima, Perú
19 (V.A. Alarcón, W.S. Solís Tupes, T. Avalos-Cruz, E. Abregu)

20 Instituto de Investigación Nutricional, Lima, Perú (M. Tovar)

21 University of Cincinnati College of Medicine, Cincinnati, Ohio, USA (M.A. Huaman)

22

23

24 **Abstract**

25 From January to September 2024, a national active case-finding program in Peru's
26 prisons screened more than 38,000 incarcerated persons for tuberculosis using chest radiography
27 with automated interpretation and rapid molecular diagnostics, yielding a tuberculosis prevalence
28 of 2,800 per 100,000 persons, with 11.4% of cases rifampicin-resistant; 42.5% of cases were
29 subclinical.

30

31 **The Study**

32 Global tuberculosis (TB) incidence has slowly declined over the past decade, but prisons,
33 especially in Latin America, have seen alarming increases in TB incidence over the same period
34 (1). Overcrowding, poor ventilation, and diagnostic delays amplify tuberculosis transmission,
35 such that incidence rates in this region are 27 times higher among persons deprived of liberty
36 (PDL) compared to the general population (2). The rise in tuberculosis in Latin America's
37 prisons has more than offset reductions in TB in the general population, undermining progress
38 towards the *End TB* goals (3).

39 To address this disproportionate burden, the World Health Organization (WHO) now
40 recommends active case-finding (ACF) for TB in prisons (4). However, few standardized efforts
41 have been made to implement nationwide screening for TB in prisons in low- and middle-
42 income countries (LMICs). There remains a critical need for evidence-based, efficient
43 implementation strategies that are sustainable in real-world settings. The Peruvian National TB
44 Program (DPCTB) recently initiated a country-wide screening strategy using chest radiography
45 (CXR) with computer-detection software, clinical evaluation and molecular rapid diagnostics in
46 high TB-burdened prisons. We sought to evaluate the programmatic yield of this initiative and
47 assess how each screening component contributed to identifying tuberculosis cases.

48 Peru has a population of 34 million inhabitants and 96,805 prisoners (5,6). In 2022,
49 national TB incidence was estimated to be 151 cases per 100,000 person-years (6), while
50 incidence among PDL has been estimated to be 4,194 cases per 100,000 person-years (7). In
51 2023, DPCTB implemented an active case finding program in 12 male, 1 co-ed, and 5 female
52 prisons chosen for size, TB burden, and convenience (Figure 1).

53 Programmatic data from PDL ≥ 18 years old who were not being treated for active TB
54 and received a CXR screening between January and September 2024 were included in this
55 analysis. The screening team consisted of a physician, nurse, and radiology technician; three
56 largest prisons included additional lab personnel. Each participant was interviewed to collect
57 demographic, clinical, and TB-symptom information. All participants were screened with a
58 portable digital CXR machine, and CXR were evaluated with Computer-Aided Detection for
59 Tuberculosis (CAD4TB) software version 7.0. CAD4TB assigns a score between 1 and 100
60 based on radiological abnormalities suggestive of a TB diagnosis. All participants then
61 underwent clinical evaluation by a physician.

62 Participants with a CAD4TB score ≥ 40 (considered “abnormal”) were asked to produce
63 a sputum sample. Participants with a CAD4TB score < 40 (considered “normal”) were only
64 asked to produce a sputum sample if the physician suspected TB based on symptoms and/or
65 evaluation. A molecular rapid diagnostic test, Xpert MTB/RIF Ultra assay (Cepheid, Sunnyvale;
66 hereinafter Xpert), was performed on all but 308 sputum samples, which were excluded from
67 analysis. We defined a TB case as any positive or trace sputum Xpert result. All individuals with
68 confirmed TB were provided free treatment.

69 Between January and September of 2024, DPCTB screened 38,734 participants meeting
70 inclusion criteria: 7,291 (18.8%) had sputum collected, and 6,873 (94.3%) of samples produced

71 valid Xpert results (Figure 2). To evaluate the association between demographic and clinical
72 characteristics and TB, we used multivariable logistic regression with fixed effects for prison to
73 estimate crude (OR) and adjusted (AOR) odds ratios with their respective 95% confidence
74 intervals. We calculated the sputum positivity and proportion of TB cases detected by
75 combinations of symptom screen and CAD4TB results (Table 2). R (version 4.4.1) was used for
76 statistical analyses.

77 Most study participants were male (96%), born in Peru (94%), and median age was 35
78 years old (IQR 27-43). Previous TB history was reported among 16% of participants, and 40%
79 reported prior contact with TB (Table 1).

80 Among all participants, 1,089 (2.8%) were diagnosed with TB. Prevalence ranged from
81 0% in several small prisons (<250 PDL) to 5.6% among 2,053 PDL in Huacho. All five female
82 prisons had a prevalence under 1.5%, while 8 of the 12 male prisons had TB prevalence over 2%.
83 11.4% (124/1089) of Xpert-positive samples tested positive for rifampicin resistance (RR-TB),
84 with four prisons recording RR-TB prevalence among cases of over 10% (Figure 1).

85 5,908 (15.3%) participants had abnormal CAD4TB scores, and 4,613 (11.9%) reported
86 symptoms in the preceding two weeks. Xpert positivity varied substantially according to
87 symptoms and x-ray abnormality. Among individuals with symptoms but normal scores, 6.8%
88 had positive Xpert, representing 7.8% of TB cases detected. Among individuals with abnormal
89 scores but no symptoms, 12.2% had positive Xpert, representing 40.9% of TB cases. Xpert was
90 positive in 26.2% of those with symptoms and abnormal scores, who comprised 49.8% of TB
91 cases (Table 2).

92 Odds of TB were higher among participants with a reported history of TB (AOR: 2.79,
93 95% CI, 2.44-3.19) and contact with TB (AOR: 1.90, 95% CI: 1.55-2.31) (Table 1). Odds of RR-

94 TB were higher among cases with a reported history of TB (AOR: 1.95, 95% CI, 1.32-2.91)
95 (Supplementary Table 1).

96 **Conclusion**

97 There is a critical need for successful, scalable models for ACF in LMIC prisons, where
98 estimates suggest that nearly half of cases go undetected annually (7). In Peru, a mass screening
99 strategy led by mobile health teams using CXR with automated interpretation screened over
100 38,000 PDL in eight months, more than one-third of the national incarcerated population, making
101 it one of the largest scale implementations of ACF based in molecular testing in LMIC prisons
102 reported to date. The prevalence of undiagnosed TB was 2,800 per 100,000, with 11.4% of RR-
103 TB. More than 40% of individuals with Xpert-confirmed TB lacked symptoms. These findings
104 illustrate the importance of systematic screening in prisons, including among individuals without
105 TB symptoms.

106 This study also presents the first nationally representative prevalence estimates of TB
107 burden in Peru's carceral system based in molecular testing. Since 2020, Peru has remained on
108 the WHO's list of the 30 countries with the highest levels of drug-resistant TB, and it is
109 estimated that 8.3% of new TB diagnoses every year are drug-resistant (6,8). Our study detected
110 a high prevalence of TB (2,800 per 100,000), and a very high proportion (11.4%) of RR-TB. The
111 prevalence estimate was almost certainly an underestimate for these prisons, as sputum was only
112 collected from participants with x-ray abnormalities, symptoms, or clinical suspicion of TB.
113 Including clinical inference as a criterion would likely capture additional TB. However, this
114 study was limited to 18 prisons selected for high TB-burden and convenience, hindering
115 generalizability to other prisons in Peru.

116 A hidden threat in high-transmission settings like prisons in LMICs is subclinical TB.

117 Previous estimates have shown that asymptomatic TB accounts for a considerable proportion of

118 active disease and overall transmission in both the general and incarcerated population (9-12).

119 We found 42.5% of all TB cases in this study to be subclinical, likely an underestimate due to the

120 inclusion of symptoms in the screening algorithm criteria, suggesting that symptom-only case-

121 finding strategies would delay detection or miss a significant fraction of active TB among PDL.

122 Our data demonstrate that active case-finding can identify a large reservoir of

123 undiagnosed tuberculosis and can be performed efficiently at scale in prisons using mobile

124 radiography with automated interpretation led by teams of health professionals. Such strategies

125 require incorporation into national TB programs with sustainable financing to roll out and

126 maintain their implementation at scale in LMIC prisons, where the burden of TB demands urgent

127 attention.

128 **Acknowledgements**

129 We thank the Peruvian National TB Program team for providing data and assistance during this

130 study.

131 **Disclosures**

132 The authors present no conflicts of interest. This study was reviewed by the Stanford

133 Institutional Review Board and was determined not to be human subjects research. This project

134 has been registered in the INS-Peru study registry (PRISA) (EI00000003259).

135 **Biographical Sketch**

136 Ms. Jung is a research program coordinator at Stanford University School of Medicine. Her

137 research interests include environmental and infectious disease epidemiology in marginalized

138 populations.

139 **References**

- 140 1. Walter KS, Martinez L, Arakaki-Sanchez D, Sequera VG, Sanabria GE, Cohen T, Ko AI,
141 García-Basteiro AL, Rueda ZV, López-Olarte RA, Espinal MA, Croda J, Andrews JR.
142 The escalating tuberculosis crisis in central and South American prisons. *The Lancet*.
143 2021;397(10284),1591–1596. [DOI](#)
- 144 2. Cords O, Martinez L, Warren JL, O’Marr JM, Walter KS, Cohen T, Zheng J, Ko AI,
145 Croda J, Andrews JR. Incidence and prevalence of tuberculosis in incarcerated
146 populations: A systematic review and meta-analysis. *The Lancet Public Health*. 2021;6(5).
147 [DOI](#)
- 148 3. World Health Organization. The End TB Strategy: Global strategy and targets for
149 tuberculosis prevention, care and control after 2015. 2014 [cited 2024 Aug 23].
150 <https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19>
- 151 4. World Health Organization. Consolidated guidelines on tuberculosis: Module 2:
152 screening – systematic screening for tuberculosis disease. 2021 [cited 2024 Aug 2].
153 <http://www.ncbi.nlm.nih.gov/books/NBK569338/>
- 154 5. World Prison Brief. Peru. 2024 Apr 30 [cited 2024 Jul 13].
155 <https://www.prisonstudies.org/country/peru>
- 156 6. World Health Organization. TB profile. 2022 [cited 2024 Aug 13].
157 [https://worldhealthorg.shinyapps.io/tb_profiles/?inputs_entity_type=%22country%22](https://worldhealthorg.shinyapps.io/tb_profiles/?inputs_entity_type=%22country%22&iso2=%22PE%22&lan=%22EN%22)
158 [&iso2=%22PE%22&lan=%22EN%22](https://worldhealthorg.shinyapps.io/tb_profiles/?inputs_entity_type=%22country%22&iso2=%22PE%22&lan=%22EN%22)
- 159 7. Martinez L, Warren JL, Harries AD, Croda J, Espinal MA, Olarte RAL, Avedillo P,
160 Lienhardt C, Bhatia V, Liu Q, Chakaya J, Denholm JT, Lin, Y, Kawatsu L, Zhu L,
161 Horsburgh CR, Cohen T, Andrews, JR. Global, regional, and national estimates of

- 162 tuberculosis incidence and case detection among incarcerated individuals from 2000 to
163 2019: A systematic analysis. *The Lancet Public Health*. 2023;8(7), e511–e519. [DOI](#)
- 164 8. World Health Organization. Global Tuberculosis Report 2023. 2023 Nov 7 [cited 2024
165 Jul 23]. [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023)
166 [tuberculosis-report-2023](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023)
- 167 9. Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, Onozaki I, Esmail H,
168 Houben, RMGJ. Subclinical Tuberculosis Disease — A Review and Analysis of
169 Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening
170 Methodology. *Clinical Infectious Diseases*. 2020;73(3), e830–e841. [DOI](#)
- 171 10. Kendall EA, Shrestha S, Dowdy DW. The Epidemiological Importance of Subclinical
172 Tuberculosis. A Critical Reappraisal. *Am J Respir Crit Care Med*. 2021 Jan
173 15;203(2):168-174. [DOI](#).
- 174 11. Puma, D., Yuen, C. M., Millones, A. K., Brooks, M. B., Jimenez, J., Calderon, R. I.,
175 Lecca, L., Becerra, M. C., & Keshavjee, S. (2023). Sensitivity of Various Case Detection
176 Algorithms for Community-based Tuberculosis Screening. *Clinical Infectious Diseases*,
177 76(3), e987–e989. [DOI](#)
- 178 12. Puma, D., Geadas, C., Calderon, R. I., Yuen, C. M., Jiménez, J., Córdova, M., Martínez,
179 B., Peinado, J., Lecca, L., & Tovar, M. (2023). Active case-finding for TB among
180 incarcerated women in Peru. *The International Journal of Tuberculosis and Lung Disease*,
181 27(10), 784. [DOI](#)

182

183 **Table 1.** Multivariable logistic regression analysis of demographic characteristics and risk
 184 factors for tuberculosis among screened PDL.

Risk factor	n	TB Confirmed (%)	OR (95% CI)	P value	AOR (95% CI)	P value
Age						
18-29	11193	382 (3.4)				
30-44	17557	486 (2.8)	0.75 (0.65, 0.87)	<.001	0.68 (0.59, 0.78)	<.001
45-60	7708	169 (2.2)	0.58 (0.48, 0.70)	<.001	0.54 (0.45, 0.65)	<.001
≥ 60	2274	52 (2.3)	0.61 (0.45, 0.81)	<.001	0.58 (0.42, 0.77)	<.001
Sex						
Male	37227	1081 (2.9)	5.01 (1.60, 30.3)	.024	3.78 (1.20, 22.94)	.062
Female	1507	8 (0.5)				
TB History						
Yes	6232	397 (6.4)	2.85 (2.50, 3.24)	<.001	2.75 (2.41, 3.13)	<.001
No	32502	692 (2.1)				
TB Contact	15459	556 (3.6)	2.15 (1.77, 2.59)	<.001	1.90 (1.56, 2.30)	<.001
Peru Origin	36596	1054 (2.9)	1.80 (1.30, 2.58)	.001	1.67 (1.20, 2.41)	.004

185 Data are presented as no. (%) unless otherwise indicated. CI, confidence interval; PDL, persons deprived of liberty;

186 TB, tuberculosis; OR, odds ratio; AOR, adjusted odds ratio; PDL, persons deprived of liberty.

187 **Table 2.** Predictive value of Computer-Aided Detection for Tuberculosis Score, symptom
188 screen, and sputum collection among screened PDL.

CAD4TB Score	Symptoms	n (%)	Sputum Collected	TB Confirmed	% of TB Cases* (95% CI)	Sputum Positivity % (95% CI)
< 40	Absent	30335 (78.3)	333	17	1.6 (0.9, 2.5)	5.1 (3.0, 8.1)
	Present	2491 (6.4)	1250	85	7.8 (6.3, 9.6)	6.8 (5.5, 8.3)
≥ 40	Absent	3786 (9.8)	3642	445	40.9 (37.9, 43.9)	12.2 (11.2, 13.3)
	Present	2122 (5.5)	2066	542	49.8 (46.8, 52.8)	26.2 (24.4, 28.2)
Total		38734	7291	1089		

189 *TB case defined as any positive or trace Xpert result. CAD4TB, Computer-Aided Detection for Tuberculosis; CI,
190 confidence interval; TB, tuberculosis; PDL, persons deprived of liberty.

191
192
193
194
195
196

197 **Figure 1.**

198 Figure Legend:

199 Panel A - Map of 18 prisons included in screening procedures, insets magnify Lima/Callao and
200 Piura districts.

201 Panel B - Bar diagram displaying tuberculosis prevalence and rifampicin-resistance (RR-TB) by
202 prison, sorted by descending TB prevalence. Dotted line shows overall TB prevalence across all
203 prisons (2.8%).

204 *TB case defined as any positive or trace Xpert result. EP, Establecimiento Penitenciario
205 (Penitentiary Establishment); Juvenil Miguel Grau, Centro Juvenil de Diagnóstico y
206 Rehabilitación Miguel Grau; Mujeres, women's prison, RR-TB, rifampicin-resistant TB; TB,
207 tuberculosis, Varones, men's prison.

208

209 **Figure 2.**

210 Figure Legend:

211 Flowchart for tuberculosis screening algorithm across 18 study prisons among included
212 participants.

213 *TB case defined as any positive or trace Xpert result. CAD4TB, Computer-Aided Detection for
214 Tuberculosis; MTB, Mycobacterium tuberculosis; PDL, persons deprived of liberty; TB,
215 tuberculosis.

216

217

218

219

220

221



